STAT Plus: Coronavirus fears may slow clinical trials and delay regulatory steps
Initially, plans for the huge clinical trial were proceeding apace. After months of groundwork, about…
Category: STAT Plus
STAT Plus: Pharmalittle: Shortage of a key chemical slows coronavirus testing; CMS touts pilot program to lower insulin costs
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT Plus: Biotech, bracing for widespread coronavirus fallout, hopes for the best and prepares for the worst
Biotech: Disrupted. As the number of Covid-19 cases expand globally, every corner of the biotech…
STAT Plus: FDA rejects Intarcia’s diabetes implant for a second time
For the second time, the Food and Drug Administration rejected an Intarcia Therapeutics implant aimed…
STAT Plus: Drug companies, Canadians, pharmacists and more blast Trump’s drug importation plan
WASHINGTON — The Trump administration is being flooded with opposition to its plan for allowing…
STAT Plus: Global companies expand the reach of their cancer drugs in China
While much of the world is understandably focused on the new coronavirus’s emergence in China,…
STAT Plus: Pharmalittle: Gates Foundation and others plan $125 million coronavirus effort; India considers lifting export restrictions
Rise and shine, everyone, another busy day is clearly on the way. The world seems…
STAT Plus: Clinical research company sued over stolen trade secrets after employee filmed dogs used in experiments
Nearly two years ago, Charles River Laboratories (CRL) paid $800 million for a company called…
STAT Plus: Debates over biosimilar uptake notwithstanding, sales growth should accelerate by 2024
Despite various issues that have slowed biosimilar uptake by the U.S. health care system, usage…
STAT Plus: ‘Unleash that data’: Medicare chief promotes freer exchange of medical records, highlights efforts to protect privacy
After a year of intense lobbying, the Trump administration on Monday finalized federal rules to…
STAT Plus: A recently approved Gilead HIV prevention pill is not cost-effective and should be cut in half, study says
The price of a Gilead Sciences (GILD) pill approved in the U.S. last fall to…
STAT Plus: Pharmalittle: Will some coronavirus vaccines make infections worse? Not all biopharma execs have prepared
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: Pharmalittle: Former Gates Foundation chief is ‘very worried’ about coronavirus; FDA does little to clarify CBD rules
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: Private equity firms are increasingly buying up doctors’ offices. What does that mean for doctors — or for patients?
WASHINGTON — Can private equity firms provide quality health care? It’s the question that patients,…
STAT Plus: Congress asked the FDA to explain its rules on CBD — but its new report offers little clarity
WASHINGTON — A new report on cannabidiol, or CBD, from the Food and Drug Administration,…
STAT Plus: Gene and cell therapies continue growth in patients, financing, and costs
The number of people treated with approved gene therapies and gene-modified cell therapies like CAR-T…
STAT Plus: The Engine at MIT is revving up the potential of ‘tough tech’
If you happen to bump into Bill Gates or Tim Cook in Central Square in…
STAT Plus: Pharmalittle: Coronavirus vaccine testing starts in Seattle area; New Mexico law caps monthly insulin co-pay at $25
Hello, everyone, and how are you today? We are doing just fine, thank you, courtesy…
STAT Plus: Oh, Canada! Vertex battles another country over access to cystic fibrosis treatments
A row has broken out between Vertex Pharmaceuticals (VRTX) and Canadian officials over access to…
STAT Plus: What to expect at health tech’s big HIMSS conference — if it happens
An earlier version of this story appeared in STAT’s Health Tech newsletter. Click here to subscribe….
STAT Plus: Pharmalittle: Vaccine affordability a roadblock to coronavirus funding; developing a drug costs how much?
Top of the morning to you and a fine one, it is. A shiny sun…
STAT Plus: This biotech went public during the stock market’s worst week since 2008
Concerns about the coronavirus outbreak made last week one of the markets’ worst since the…
Justice Department sues Mallinckrodt over ‘hundreds of millions of dollars’ in Medicaid rebates
A simmering feud between the federal government and Mallinckrodt (MNK) took a new turn as…
STAT Plus: TG Therapeutics cops to another blood cancer drug trial delay, as excuses wear thin
TG Therapeutics (TGTX) on Tuesday delayed yet again the readout from its most important blood…
STAT Plus: Drug prices rose three times faster than inflation over the past decade, despite discounts
Amid intensifying anger over the rising cost of medicines, a key piece of data has…
STAT Plus: New estimate says developing a drug costs $1.3 billion, which is a lot, but less than companies often say
Estimates of how much it cost to invent and test a new medicine have been…
STAT Plus: Thermo Fisher buys Dutch diagnostics company for $11.5 billion
Thermo Fisher Scientific (TMO) is buying the Dutch diagnostics company Qiagen (QGEN) in an $11.5…
STAT Plus: Pharmalittle: Trump’s contempt for pharma melts away; India restricts exports of 26 ingredients due to coronavirus
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT Plus: Contract spells out how the University of Chicago shared patient data with Google
SAN FRANCISCO — In December 2016, Google and the University of Chicago signed a contract…
STAT Plus: Novartis generic unit to pay $195 million to settle price fixing charges
In the latest fallout from a federal probe into generic drug price fixing, the Sandoz…
STAT Plus: California slams AmerisourceBergen over opioid shipments to pharmacies
The California Board of Pharmacy cancelled a wholesale license for AmerisourceBergen (ABC) and fined the…
STAT Plus: Cancer biotech gets another new name (now it’s called Xilio) and more than $100 million
For the second time in less than two years, Akrevia Therapeutics has changed its name, in…
STAT Plus: CEO Daniel O’Day explains why Gilead paid $4.9 billion for Forty Seven
Gilead’s board hired CEO Dan O’Day a year ago to look for new areas of…
STAT Plus: FDA petitioned to recall batches of metformin diabetes pill over a possible carcinogen
An online pharmacy is calling for U.S. regulators to recall batches of the metformin diabetes…
STAT Plus: Pharmalittle: Experts warn political squabbles should not delay coronavirus funding; Gilead to buy Forty Seven for $5 billion
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: Karyopharm to seek expanded use of multiple myeloma drug following positive clinical trial
Karyopharm Therapeutics (KPTI) said Monday that the primary goal was achieved in a clinical trial…
STAT Plus: Something Ventured: Vor Biopharma and 3 other startups got venture funding a year ago. Did it help them do what they said it would?
This story is part of STAT’s quarterly series Something Ventured, which looks at early-stage startups….
.jpg)
STAT Plus: Sanofi to pay nearly $12 million for illegally using a charity to pay kickbacks to Medicare patients
Sanofi (SNY) has agreed to pay nearly $11.9 million to resolve allegations that donations paid…
STAT Plus: Cardinal Health to pay $8 million for failing to prevent bribes paid in China
Cardinal Health (CAH), one of the largest pharmaceutical wholesalers, agreed to pay more than $8…
STAT Plus: Novartis employee claims she was fired for complaining about incorrect data
As Novartis (NVS) geared up to win approval for a new eye medication that was…
STAT Plus: Pharmalittle: Azar says Medicare is open to price negotiations; drug makers say opioid settlements are in jeopardy
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: Turned away from five clinical trials, a cancer patient waits for one that will take him
It’s hard enough for any cancer patient to get into clinical trials. It’s even harder…
STAT Plus: AI has arrived in medical imaging. Now the FDA needs to monitor its impact on patients
BETHESDA, Md. — This is the moment of truth for the FDA’s regulation of artificial…
STAT Plus: They have ‘Alzheimer’s brains’ but no symptoms. A new wave of drug developers wants to know why
For years they were flukes of the Alzheimer’s world: elderly people who died at an…
.jpg)
STAT Plus: Pharmalittle: Gilead accelerates coronavirus trial; FDA says coronavirus vaccine will take time
Rise and shine, everyone, another busy day is on the way. This is a fast-paced…
STAT Plus: Health care conference about conflicts of interest has a conflict itself, say critics who won’t attend
In an effort to better understand how conflicts of interest may affect health care, the…
STAT Plus: Senators threaten to subpoena Express Scripts for failing to produce insulin documents
The ranking members of the Senate Finance Committee are threatening to issue a subpoena to…
STAT Plus: Tracking pharmaceuticals in the supply chain remains difficult due to sloppy paperwork
As Americans debate whether to import prescription drugs from Canada to relieve rising costs, a…
STAT Plus: Pharmalittle: FDA tracks 20 drugs for shortage risk due to coronavirus; GOP senator moves toward Medicare drug negotiations
Top of the morning to you. Another busy day is unfolding here on the Pharmalot…
STAT Plus: Allakos is running clinical trials in reverse, critics say, raising questions about its digestive disease drug
Allakos (ALLK) is embroiled in a clinical trial controversy with potentially billions of dollars at…